Drug Therapy for Rheumatoid Arthritis in Adults
Comparative Adverse Effects of DMARDs for Patients With Early Rheumatoid Arthritis
Adding prednisone to treatment with one or multiple oral disease-modifying anti-rheumatic drugs (DMARDs) does not increase treatment discontinuation rates (treatment durations spanned 2 months to 5 years). The strength of evidence for this finding is moderate.
Combining oral DMARDs (sulfasalazine and methotrexate) increases withdrawal from treatment due to adverse events. The strength of evidence for this finding is low.
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | methotrexate | oral DMARD | biologic DMARD | adverse effects | prednisone | sulfasalazine | methotrexate
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.